Qube Research & Technologies (QRT)
HRTX icon

Qube Research & Technologies (QRT)’s Heron Therapeutics HRTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.3K Buy
+30,355
New +$35.2K ﹤0.01% 3258
2025
Q3 		– Sell
-132,782
Closed -$275K – 3753
2025
Q2 		$275K Buy
+132,782
New +$271K ﹤0.01% 2840
2024
Q4 		– Sell
-1,146,658
Closed -$2.28M – 3620
2024
Q3 		$2.28M Buy
1,146,658
+639,431
+126% +$1.53M ﹤0.01% 1713
2024
Q2 		$1.78M Sell
507,227
-54,757
-10% -$168K ﹤0.01% 1689
2024
Q1 		$1.56M Buy
+561,984
New +$1.41M ﹤0.01% 1886
2023
Q4 		– Sell
-6,021
Closed -$6.2K – 4505
2023
Q3 		$6.2K Buy
+6,021
New +$8.57K ﹤0.01% 3409
2023
Q1 		– Sell
-502,756
Closed -$1.26M – 2738
2022
Q4 		$1.26M Buy
502,756
+399,171
+385% +$1.29M 0.01% 1116
2022
Q3 		$437K Buy
103,585
+24,288
+31% +$95K ﹤0.01% 1519
2022
Q2 		$221K Buy
79,297
+2,216
+3% +$8.9K ﹤0.01% 1691
2022
Q1 		$441K Buy
+77,081
New +$564K ﹤0.01% 1590
2020
Q2 		– Sell
-11,543
Closed -$136K – 1834
2020
Q1 		$136K Sell
11,543
-5,687
-33% -$107K 0.01% 925
2019
Q4 		$405K Buy
+17,230
New +$381K 0.01% 1061

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Qube Research & Technologies (QRT)'s HRTX Position: Q1 2026 in Review

Qube Research & Technologies (QRT) opened a new position in Heron Therapeutics (HRTX) in Q1 2026: 30,355 shares worth $24.3K. The stake represents ﹤0.01% of the portfolio and ranks #3258 among its holdings. This is a return to the name: Qube Research & Technologies (QRT) previously reported a position in HRTX as recently as Q2 2025.

Qube Research & Technologies (QRT) first reported a position in HRTX in Q4 2019 and has held it in 12 quarters since. The position peaked at $2.28M in Q3 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Qube Research & Technologies (QRT) held 30,355 shares of Heron Therapeutics worth $24.3K as of Q1 2026.
  • Heron Therapeutics was a new Qube Research & Technologies (QRT) position in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #3258 holding.
  • Qube Research & Technologies (QRT) first reported a position in Heron Therapeutics in Q4 2019 and has held it in 12 quarters since.
  • Qube Research & Technologies (QRT)'s Heron Therapeutics position peaked at $2.28M in Q3 2024.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.